Dimerisation of the VIP receptor VIPR2 is essential to its binding VIP and Gα<sub>i</sub> proteins, and to its functions in breast cancer cells
Dimeric VIPR2 forms the minimal functional unit that effectively promotes growth and metastasis of breast cancer. Therefore, dimeric VIPR2 is a potential therapeutic target for breast cancer, and TM3-4-peptides are potential anti-cancer drug candidates to suppress cancer progression.
Authors
- Yukio Ago
- S Asano (ORCID: https://orcid.org/0000-0003-1537-4307)
- Takanobu Nakazawa (ORCID: https://orcid.org/0000-0003-4863-1277)
- Rei Yokoyama (ORCID: https://orcid.org/0009-0000-7595-4632)
- Kairi Ozasa
- Souichi Yanamoto (ORCID: https://orcid.org/0000-0003-2372-8347)
- Teru Uehara
Institutions
- Hiroshima University (JP)
- Tokyo University of Agriculture (JP)
Publication Details
- Journal
- British Journal of Pharmacology
- Published
- 2025-04-09
- DOI
- https://doi.org/10.1111/bph.70039
- Citations
- 3
- Primary Topic
- Neuropeptides and Animal Physiology
- Type
- article
- Field-Weighted Citation Impact
- 2.73
Funders
- Japan Agency for Medical Research and Development
- Tokyo Biochemical Research Foundation
- Japan Society for the Promotion of Science